

























LIST	OF	ABBREVIATIONS	3TC	 lamivudine	ABC	 abacavir	ACC	 American	College	of	Cardiology	ACTG	 AIDS	Clinical	Trials	Group	AHA	 American	Heart	Association	AIDS	 acquired	immune	deficiency	syndrome	ASCVD	 atherosclerotic	cardiovascular	disease	ART	 antiretroviral	therapy	ATP	 Adult	Treatment	Panel	CHD	 coronary	heart	disease	CVD	 cardiovascular	disease	CI	 confidence	interval	CNICS	 Center	for	AIDS	Research	Network	of	Integrated	Clinical	Systems	d4T	 stavudine	ddI	 didanosine	DRV	 darunavir	FTC	 emtricitabine	HDL	 high	density	lipoprotein	HIV	 human	immunodeficiency	virus	IP	 inverse	probability	LDL	 low	density	lipoprotein	NNRTI	 non-nucleoside	reverse	transcriptase	inhibitor	
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TABLE	1.1:	Markers	of	dyslipidemia	among	HIV-positive	patients	in	the	USA,	Europe,	and	Australia	Study,	Year	 Study	Type	 Study	Population	 N	 Total	Cholesterola	 LDL	Cholesterola	 Triglyceridesa	 Remarks	Behrens,	2012	 Open-label	RCTb	 Patients	with	elevated	total	cholesterol,	switching	from	ABC/3TC	to	TDF/FTCb	 85	 TDF/FTC:	-28	 ---	 ---	 Lower	median	cholesterol	in	TDF/FTC	group	after	switch	Taiwo,	2011	 Prospective	cohort	 ART-naïve,	beginning	DRV/ritonavir	+	RALb	 112	 30	 17	 Increases	in	TC,	LDL-C,	and	triglycerides	on	NRTI-sparing	regimenbStein,	2008	 RCT	 ART-naive	 82	 NRTI-sparing:	65	NNRTI-sparing:	21	PI-sparing:	18	 NRTI-sparing:	26	NNRTI-sparing:	7	PI-sparing:	6	 NRTI-sparing:	83	NNRTI-sparing:	72	PI-sparing:	22	 Highest	lipid	increases	in	NRTI-sparing	group	Riddler,	2007	 Retrospective	cohort	 Homosexual/bisexual	men,	ART-naïve	 304	 42	 22	 ---	 Maximum	lipid	increases	2-3	years	after	ART	initiation	Llibre,	2006	 Prospective	cohort	 Patients	on	stable	ART,	switching	from	d4Tb	to	TDF	 352	 -17.5 -8.1 -35 Lower	median	lipid	values	after	switch	from	d4T	to	TDF	Crane,	2011	 Prospective	cohort	 PI/NNRTI-naive	 2,267	 Baseline:	128	12	months:	153	36	months:	153	 Baseline:	88	12	months:	98	36	months:	97	 Baseline:	120	12	months:	145	36	months:	149	 Rapid	increases	in	lipid	values	within	one	year	of	therapy;	levels	off	after	a	year.	Tenofovir	had	best	lipid	profile	Friis-Moller,	2003	 Cross-sectional	 General	HIV+	 17,852	 ART-naïve:	170	NNRTI:	205	PI:	205	PI/NNRTI:	228	
---	 ARV-naïve:	115	NNRTI:	142	PI:	168	PI/NNRTI:	221		
Baseline	TC	and	triglyceride	levels	were	highest	in	the	PI/NNRTI	group	
Saint-Marc,	2000	 Cross-sectional	 Men	 154	 ART-naïve:	184	NRTI:	188	PI:	230	 ART-naïve:	114	NRTI:	111	PI:	137	 ART-naïve:	115	NRTI:	173		PI:	273	 Lipid	profile	much	worse	for	patients	on	PI	therapy	Galli,	2002	 Prospective	cohort	 NOT	ART-naïve;	no	prior	lipodystrophy	 335	 11	 ---	 23	 Risk	of	hypertriglyceridemia	higher	in	d4T-treated	patients	Chêne,	2002	 RCTc	 ART-naive	 120	 40	 ---	 25	 Relatively	high	levels	of	dyslipidemia	at	baseline	a	Median	values	in	mg/dL	b	Acronyms:	RCT	–	randomized	clinical	trial;	ABC	–	abacavir;	3TC	–	lamivudine;	TDF	–	tenofovir	disoproxil	fumarate;	FTC	–	emtricitabine;	ACTG	–	AIDS	Clinical	Trials	Group	(22	sites	in	USA);		ART	–	antiretroviral	therapy;	DRV	–	darunavir;	RAL	–	raltegravir;	TC	–	total	cholesterol;	LDL	–	low	density	lipoprotein;	CNICS	–	Center	for	AIDS	Research	Network	of	Integrated	Clinical	Systems;		d4T	–	stavudine;	ddI	-	didanosine	c	RCT	for	6	months,	followed	by	24	months	of	prospective	follow-up
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TABLE	1.4:	Studies	involving	statin	use	in	HIV	infected	patients	Study,	Year	 Location	 Study	Type	 Study	Population	 N	 Comparison	 LDL	Cholesterol	or	total	cholesterola	 Remarks	Silverberg,	2009	 USA,	Kaiser	Permanente	 Retrospective	cohort	 New	users	of	statins	 829	HIV+,	6941	HIV-	 HIV	serostatus	 LDL	cholesterol	HIV+:	-25.6%	HIV-:	-28.3%	 LDL/triglycerides	reduction	smaller	in	HIV+	group.	Limited	number	of	women.	Lo,	2015	 USA	 RCT	 HIV+	with	subclinical	coronary	atherosclerosis	 40	 Atorvastatin	vs.	placebo	 LDL	cholesterol	(mean)	Atorvastatin:	-39mg/dL	Placebo:	12mg/dL	 No	difference	between	statin	arm	and	placebo	on	aterial	inflammation	of	the	aorta	Eckard,	2014	 USA	 RCT	 HIV+	w/fasting	LDL	≤130	mg/dL		 147	 Rosuvastatin	vs.	placebo	 LDL	cholesterol	Rosuvastatin:	-28%	Placebo:	4%	 Trial	was	designed	to	look	at	markers	of	vascular	inflammation,	no	difference	between	groups.	Singh,	2011	 USA,	CNICS	 Retrospective	cohort	 New	users	of	statins	 700	 Pravastatin	vs.	atorvastatin	vs.	rosuvastatin	 LDL	cholesterol	Pravastatin:	-12mg/dL	Atorvastatin:	-26mg/dL	Rosuvastatin:	-23mg/dL	
























TABLE	3.1:	General	WIHS	Population	Characteristics	at	Study	Entry	Characteristic	 Overall	(N=4582)	 HIV+	(N=3374)	 HIV-	(N=1208)	Age	 36	(30,	42)	 37	(31,	43)	 35	(27,	42)	Race						Black	 2835	(62)	 2076	(62)	 759	(63)						White	 975	(21)	 724	(21)	 251	(21)						Other	 772	(17)	 574	(17)	 198	(16)	Hispanic	Ethnicity	 443	(10)	 310	(9)	 133	(11)	Smoking	History		Current	 2372	(52)	 1685	(50)	 687	(57)						Former	 704	(15)	 550	(16)	 154	(13)						Never	 1506	(33)	 1139	(34)	 367	(30)	ART	Regimen						No	therapy	 ----	 1210	(36)	 ----						Monotherapy	 ----	 682	(20)	 ----						Combination		 ----	 635	(19)	 ----						HAART	 ----	 847	(25)	 ----	*25	patients	seroconverted	from	HIV-	to	HIV+	and	were	excluded
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𝐿 𝛽 = 𝑌! 𝑡 exp 𝛽𝐴!𝑌! 𝑡 exp 𝛽𝐴!!∈! ! !! !!!!!	We	used	inverse	probability	weights	to	control	for	confounding	and	loss	to	follow	up.	The	stabilized	weights	𝑊!" 𝑡 	can	be	expressed	as	the	product	of	a	time-fixed	weight	for	exposure	WA,	and	a	time-varying	weight	for	drop	out	𝑊! 𝑡 .	The	denominator	for	the	exposure	weights	𝑊!	are	estimated	from	a	logistic	regression	model	𝑃 𝐴 = 1 = expit 𝛽! + 𝛽!!!!! 𝑍!!! ,	and	the	numerator	for	the	exposure	weights	can	be	estimated	from	an	intercept-only	logistic	regression	model.	We	estimate	drop	out	weights	using	quintiles	of	the	observed	drop	out	time	distribution.	The	denominator	for	the	drop	out	weights	𝑊!	is	estimated	via	a	pooled	logistic	regression	model:	






𝐸 𝑌 = 𝛽! + 𝛽!𝐴 + 𝛽!!!!! 𝑍!!!	
3.4.3	Targeted	Maximum	Likelihood	Estimation	Our	implemention	of	the	TMLE	can	be	split	into	two	distinct	steps:	initial	estimation	of	the	outcome	using	the	SuperLearner	algorithm,	and	a	targeting	step	to	reduce	mean	squared	error	from	the	initial	estimate.	Note	that	SuperLearner	is	not	required	to	implement	TMLE;	the	initial	estimation	of	the	outcome	can	be	done	using	a	parametric	
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regression	estimator,	for	example.	Under	assumptions	of	treatment	variation	irrelevance	(68),	no	interference	(69),	positivity,	and	exchangeability	(62,70),	the	TMLE	produces	causal	estimates	that	are	targeted	to	the	parameter	of	interest	(59-60).	Suppose	we	have	a	dataset	with	n	observations,	with	complete	data	on	Y,	A,	and	Z.	We	wish	to	estimate	the	marginal	risk	of	the	exposure	A	on	the	outcome	Y,	controlling	for	the	covariates	Z1,	Z2,	and	Z3.	Specifically,	we	will	estimate	the	following	risk	ratio	Ψ:	Ψ = 𝐸!,! 𝐸! 𝑌|𝐴 = 1,𝑍  / 𝐸! 𝑌|𝐴 = 0,𝑍 	The	SuperLearner	produces	an	initial	(untargeted)	estimate	of	Q0,	or	the	probability	of	the	outcome	given	exposure	and	covariates,	using	cross-validation	of	several	different	algorithms.	The	steps	involved	in	the	SuperLearner	are	as	follows:	
1. Split	the	sample	into	V	separate	blocks.2. Fit	each	algorithm	to	V-1	of	the	blocks	(the	“training	set”).3. Using	the	coefficients	generated	from	the	training	set	fit	and	the	remaining	block(the	“validation	set”),	output	predicted	probabilities	for	each	algorithm.	The	vector
D	contains	the	set	of	predicted	probabilities	for	each	algorithm.4. Repeat	Steps	2	and	3	with	each	fold	as	the	validation	set.5. Calculate	the	cross-validated	mean	squared	error	for	each	algorithm:





𝐻 𝐴,𝑍 ≡  𝐼(𝐴 = 1)𝑔 1  𝑍) −  𝐼(𝐴 = 0)𝑔 0  𝑍)3. Run	a	logistic	regression	of	the	outcome	Y	on	the	clever	covariate,	with	the	logit	ofthe	Q0	estimate	used	as	an	offset,	to	obtain	an	estimate	of	the	coefficient	ε	(theregression	coefficient	for	the	clever	covariate).
24
4. Use	this	coefficient	ε	to	update	the	initial	estimate	of	Q0	to	an	updated	estimate,	Q1.Iterate	this	process	until	the	coefficient	ε	converges	to	0,	resulting	in	the	targetedestimate	QTMLE.	Note	that	QTMLE	is	calculated	for	each	observation	in	the	data	set.5. Repeat	Steps	3	and	4	for	A=1	and	A=0,	resulting	in	values	of	QTMLE	for	both	exposurelevels.	Risk	differences	and	ratios,	denoted	by	𝜓!"#$,	can	be	calculated	from	thesevalues.6. To	generate	estimates	of	precision,	calculate	the	influence	curve	(IC):
𝐼𝐶 =  𝐼 𝐴! = 1𝑔 1 | 𝑊! −  𝐼 𝐴! = 0𝑔 0 | 𝑊! 𝑌 −  𝑄!"#$ 𝐴!,𝑊!  +  𝑄!"#$ 1,𝑊! − 𝑄!"#$ 0,𝑊!−  𝜓!"#$	7. From	the	influence	curve,	a	sample	variance	can	be	calculated,	allowingconstruction	of	confidence	intervals	and	p-values:


































Risk	 RD	(95%	CI)	 RR	(95%	CI)	 HR	(95%	CI)	
5	year	risk					Unadjusted									HIV-uninfected									HIV-infected	 150	323	 40	110	 0.30	0.38	 0	0.08	(-0.02,	0.18)	 1	1.27	(0.88,	1.66)	 1	1.37	(0.95,	1.97)					Weighteda										HIV-uninfected									HIV-infected	 151	328	 51	104	 0.38	0.37	 0	-0.01	(-0.14,	0.12) 1	0.98	(0.62,	1.34)	 1	0.95	(0.63,	1.44)	
2	year	risk					Unadjusted									HIV-uninfected									HIV-infected	 150	323	 23	56	 0.16	0.18	 0	0.02	(-0.05,	0.09)	 1	1.12	(0.65,	1.59)					Weighteda						HIV-uninfected									HIV-infected	 151	328	 29	52	 0.20	0.17	 0	-0.04	(-0.13,	0.06) 1	0.82	(0.39,	1.24)	
1	year	risk					Unadjusted									HIV-uninfected									HIV-infected	 150	323	 12	31	 0.08	0.10	 0	0.01	(-0.04,	0.07)	 1	1.17	(0.43,	1.91)					Weighteda											HIV-uninfected									HIV-infected	 151	328	 19	30	 0.13	0.09	 0	-0.03	(-0.11,	0.04) 1	0.73	(0.18,	1.28)	
Framingham	Risk	Scoreb	
























5.2.3	Statistical	Analysis	Let	our	observed	data	be	represented	as	𝑂! = 𝑊,𝐴,𝑌 ! ,	where	𝑊! , 𝑗 = 1 to 𝑝,	are	the	𝑝	components	of	the	covariate	vector	𝑊,	𝐴	represents	the	exposure	of	interest	(HIV	serostatus)	with	possible	values	𝑎 = 1	for	HIV-infected	women	and	𝑎 = 0	for	HIV-uninfected	women,	and	𝑌	represents	a	continuous	outcome	variable,	change	in	LDL	cholesterol,	measured	in	mg/dL.	Uppercase	letters	denote	random	variables,	while	lowercase	letters	denote	possible	realizations	of	variables,	or	constants.		
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We	fit	the	linear	regression	𝐸 𝑌 = 𝛽! + 𝛽!𝐴 + 𝛽!𝑊!!!!!!!!! ,	to	estimate	the	one	year	change	in	LDL	cholesterol.	As	a	second	modeling	approach,	we	used	targeted	maximum	likelihood	estimation	(TMLE)	with	super	learning.	TMLE	allows	the	estimation	of	causal	effects	under	the	assumptions	of	treatment-variation	irrelevance,	conditional	exchangeability,	and	positivity	(68,	94-95).	Unlike	a	Gaussian	model	estimated	using	maximum	likelihood,	TMLE	does	not	require	the	specification	of	a	correct	parametric	form	for	the	outcome	model.	Such	an	estimator	has	several	desirable	properties:	it	is	doubly	robust	(96),	can	leverage	a	diverse	collection	of	algorithms	in	addition	to	traditional	regression	models,	and	minimizes	bias	and	variance	for	the	particular	target	causal	quantity,	rather	than	potential	nuisance	parameters	such	as	confounders	(59-60).	TMLE	does	have	limitations:	it	is	computationally	intensive,	and	is	less	than	fully	parametrically	efficient.	However,	TMLE	is	semiparametrically	efficient	(meaning	this	estimator	is	a	maximally	efficient	member	of	the	set	of	regular	asymptotically	linear	semiparametric	estimators)	(59-60).	Appendix	1	includes	a	more	detailed	description	of	TMLE.	As	a	secondary	aim,	among	those	women	infected	with	HIV,	we	estimated	the	effect	of	a	concomitant	PI	regimen,	in	comparison	to	women	concomitantly	on	any	other	type	of	ART,	on	longitudinal	LDL	cholesterol	changes.	For	this	secondary	aim,	we	excluded	HIV-uninfected	women	and	those	HIV-infected	women	not	on	ART.	We	also	used	both	linear	regression	and	TMLE	for	this	secondary	aim.	To	appropriately	account	for	observations	with	missing	data,	we	used	an	inverse	probability	weighted	complete	case	analysis	approach.	Let	𝑅 = 1	indicate	a	complete	case	(i.e.	no	missing	data	for	all	relevant	variables	𝑊,	𝐴,	and	𝑌).	We	fit	a	model	for	the	logit	𝑃 𝑅 = 1|𝐴,𝑉 ,	where	logit	𝑝 =	log 𝑝/ 1− 𝑝 .	𝑉	is	the	subset	of	𝑊	with	completely	
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42	11	37	5	6	0	Age	 47	(42,	53)	 49	(43,	54)	Race:						Black						White						Other	 274	119	88	 57	25	18	 125	23	30	 70	13	17	Smoking	 181	 38	 96	 54	Education:						<12	years						12	years	>12	years 182	133	165	 38	28	34	 69	50	59	 39	28	33	LDL	cholesterol	 126	(102,	153)	 121	(95,	153)	HDL	cholesterol	 46	(36,	60)	 48	(39,	63)	Total	cholesterol	 215	(183,	245)	 208	(172,	236)	Triglycerides	 162	(109,	248)	 124	(87,	186)	Any	insurance	 468	 97	 154	 87	CD4	cell	count	 565	(394,	776)	Log10	HIV	RNA	 2.3	(2.3,	2.5)	ART	use	 453	 94	AIDS	diagnosis	 205	 43	PI	use	 257	 53	Abbreviations:	 IQR,	 interquartile	 range;	 LDL,	 low	 density	 lipoprotein;	 HDL,	 high	 density	lipoprotein;	ART,	antiretroviral	therapy;	PI,	protease	inhibitor	
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TABLE	5.2:	Effects	of	HIV	and	PI	use	on	LDL	cholesterol	changes	among	women	who	
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